Abl Cytosolic Substrate

CAS No. 168202-46-8

Abl Cytosolic Substrate( —— )

Catalog No. M30182 CAS No. 168202-46-8

Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Abl Cytosolic Substrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
  • Description
    Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    168202-46-8
  • Formula Weight
    1336.58
  • Molecular Formula
    C64H101N15O16
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Glu}{Ala}{Ile}{Tyr}{Ala}{Ala}{Pro}{Phe}{Ala}{Lys}{Lys}{Lys}

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Buchdunger E, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996 Jan 1;56(1):100-4.
molnova catalog
related products
  • AKE-72

    AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.

  • Ponatinib

    Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC50 of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively.

  • DCC-2036

    DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.